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  17 
Abstract 18 
Objectives Successful early intervention in Rheumatoid Arthritis (RA) with the aim of resetting 19 
immunological tolerance requires a clearer understanding of how specificity, cellular kinetics 20 
and spatial behaviour shape the evolution of articular T cell responses. We aimed to define initial 21 
seeding of articular CD4+ T cell responses in early experimental arthritis, evaluating their 22 
dynamic behaviour and interactions with dendritic cells (DCs) in the inflamed articular 23 
environment.  24 
Methods Antigen-induced arthritis was used to model articular inflammation. Flow cytometry 25 
and PCR of T cell receptor (TCR) diversity genes allowed phenotypic analysis of infiltrating T 26 
cells. The dynamic interactions of T cells with joint residing DCs were visualized using intravital 27 
multiphoton microscopy.  28 
Results Initial recruitment of antigen-specific T cells into the joint was paralleled by 29 
accumulation of CD4+ T cells with diverse antigen-receptor expression and ability to produce 30 
TNFα and IFNγ upon mitogenic restimulation. A proportion of this infiltrate demonstrated 31 
slower motility speeds and engaged for longer periods with articular DCs in vivo. Abatacept 32 
treatment did not disrupt these interactions but did reduce T cell expression of inducible 33 
costimulatory (ICOS) molecule. We also demonstrated that non-specific CD4+ T cells could be 34 
recruited during these early articular events.  35 
Conclusions We demonstrate that CD4+ T cells engage with articular DCs supporting antigen 36 
specific T cell reactivation. This cellular dialogue can be targeted therapeutically to reduce local 37 
T cell activation.  38 
  39 
Introduction 40 
Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting the joints 1, 41 
characterized by synovial inflammation, degradation of bone and cartilage, progressive loss of 42 
function and increasing disability. As RA progresses, inflammatory cells, including T cells and 43 
dendritic cells (DCs), infiltrate the synovial compartment 2. Genome wide association studies 44 
(GWAS) support a role for T cells in the pathogenesis of RA; gene polymorphisms associated 45 
with CD4+ T cell function are associated with susceptibility to RA 3. These include HLA-DRB1, 46 
PTPN22, CD28 and CTLA-4 2, 4-6. Therapeutic targeting of T cells in RA through the use of 47 
abatacept provides evidence of their importance in disease pathogenesis.  However, there is 48 
increasing interest in characterizing the nature of the T cell response in early RA as therapeutics 49 
move increasingly in this direction.  50 
 51 
Activated CD4+ T cells are present in the inflamed joints of RA patients and appear 52 
oligoclonal in early disease 2 7 8. However, the specificity of these T cells, their site of original 53 
activation and how they mediate pathology remain unclear. Lymph node (LN) interactions 54 
between T cells and DCs will likely be critical for naïve T cell priming.  However, similar 55 
interactions could occur within the synovium, whereby joint localized reactivation of T cells 56 
would directly contribute to pathology. We employed intravital microscopy to establish the intra-57 
articular dynamics of CD4+ T cell interactions with DCs in the context of specificity and 58 
clonality in the early stages of experimental ‘early arthritis’ 9. Measurement of inducible 59 
costimulatory (ICOS) molecule was used as an indicator of T cell engagement in cognate 60 
interactions with antigen presenting cells and reception of co-stimulation via CD28 i.e. they had 61 
‘seen’ antigen. In addition, we evaluated the dependence of this dialogue on CD28 co-62 
stimulation.  63 
 64 
Methods 65 
Animals  66 
LysMGFP 10, ovalbumin specific OT-II 11 T cell receptor (TCR) transgenic (Tg) mice, OT-II 67 
DsRed and hCD2-DsRed 12 , CD11c-YFP 13 and TEa TCR RAG2-/- mice 14 were bred in house. 68 
C57BL/6J and Ly5.1 mice were purchased from Harlan (Harlan, Bicester, UK). All animals were 69 
specified pathogen free and maintained under standard animal house conditions at the University 70 
of Glasgow in accordance with UK Home Office Regulations.  71 
 72 
Induction of inflammatory arthritis 73 
ArthritoMab antibody cocktail for C57BL/6 (MD Biosciences, Zurich, Switzerland) was used to 74 
induce collagen antibody induced arthritis (CAIA).  CD4+ T cell dependent arthritis was induced 75 
as previously reported 9 15-19 (Supplementary Figure 1A). Abatacept or control IgG was 76 
administered at 10 mg/kg (Bristol-Myers Squibb) i.p. 24 hours before induction of arthritis and 77 
continuing every 2 days thereafter. For treatments 6 hours prior to imaging, arthritic mice were 78 
given 50 µl of abatacept (10 mg/kg) or etanercept (sTNFR-Fc, 0.5 mg/kg, etanercept, Wyeth 79 
Pharmaceuticals, Taplow, U.K.) into the inflamed footpad. 80 
 81 
Multiphoton laser scanning microscopy (MPLSM) 82 
Mice were anaesthetised using Domitor (50 mg/kg Ketamine and 0.5 mg/kg Medetomidine i.p.) 83 
and placed on a heated stage. Articular tissue of the lateral malleolus was surgically exposed 84 
prior to transfer to a warmed saline bath (Supplementary Figure 2A, B). MPLSM was carried out 85 
as previously reported 12. Second harmonic generation (SHG) was used to orientate the tissue 86 
once under the objective (Supplementary Figure 2C). Naïve joint of LysMGFP showing SHG in 87 
blue (Supplementary Figure 2D). CAIA inflamed joint of LysMGFP mouse showing SHG (blue) 88 
and LysMGFP expressing cells (green) (Supplementary Figure 2E). Flow cytometric analysis of 89 
leukocyte populations in both naïve and CAIA inflamed ankle joints (Supplementary Figure 2F).  90 
 91 
Recovery of cells from tissues 92 
Ankle joints were teased apart and the tissue digested for 25 minutes at 37 °C in 2.5 mg/mL 93 
collagenase D (Roche/Sigma Aldrich, Dorset, UK) in HBSS. Samples were then homogenized 94 
using Miltenyi Tissue Dissociators and strained to obtain single cell suspensions. Popliteal 95 
lymph nodes (pLN) were forced through Nitex mesh (Cadisch Precision Meshes) to obtain single 96 
cell suspensions. Cell suspensions were then washed in FACS buffer (PBS containing 2% FCS) 97 
and subsequently stained for flow cytometry.  98 
 99 
Generation of bone marrow derived dendritic cells (BMDCs) 100 
Bone marrow from C57BL/6 mice was cultured in GM-CSF conditioned medium as previously 101 
described 20. After 6 days, BMDC were cultured +/- OVA (100 µg/ml) for 2 hours before 102 
maturation overnight with the addition of Escherichia coli 055:B5 LPS (100 ng/ml) (Sigma-103 
Aldrich).  BMDC were then washed in fresh medium and co-cultured with T cells isolated from 104 
joint draining LN. 105 
 106 
Flow cytometry 107 
Cell viability was determined by Fixable Viability Dye eFluor 506 (eBioscience). Cells were 108 
subsequently washed (400 x g for 5 minutes) in FACS buffer and incubated with Fc Block for 15 109 
minutes at 4 °C prior to addition of fluorochrome-conjugated antibodies (30 minutes at 4 °C). 110 
Antibodies used (eBioscience): anti-CD3 (clone 17A2); anti-CD4 (clone GK1.5); anti-CD45 111 
(clone 30-F11); anti-CD45.1 (clone A20); anti-CD69 (clone H1.2F3); anti-CD44 (clone IM7); 112 
anti-ICOS (clone 7E.17G9); anti-CD62L (clone MEL-14); anti-CD19 (clone eBio1D3); anti-113 
MHC-II (I-A/I-E) (clone M5/114.15.2); anti-CD11c (clone N418). For fluorescence-activated 114 
cell sorting (FACS), joint draining popliteal LNs were pooled on day 4 post-HAO challenge and 115 
stained for viability, anti-CD45, anti-CD3 and anti-CD4. Live CD45+ CD3+ CD4+ T cells were 116 
isolated using a FACS Aria IIU (BD Biosciences, Oxford, UK) and co-cultured with BMDC at a 117 
1:10 ratio for 72 hours at 37 °C and 5% CO2. Intracellular cytokine staining was performed on 118 
cells isolated from joints and draining LNs using anti-IFNg (XMG1.2) and anti-TNFa (MP6-119 
XT22) following stimulation with either OVA323-339 (0.5 µg/mL) or PMA (10 ng/ml) and 120 
ionomycin (500 ng/ml) for 4 hours in the presence of brefeldin A. Cells were acquired on an 121 
LSRII (BD Biosciences) and data analysed using FlowJo software (TreeStar version 7.6.5, 122 
Oregon, USA).  123 
 124 
TCR Vβ repertoire clonality 125 
Vβ complementarity determining region 3 (CDR3) clonality was assessed using 126 
SuperTCRExpressTM (BioMed Immunotech, Florida, USA) on endogenous CD4+ T cells sorted 127 
from inflamed joints and popliteal LNs using the BD FACs ARIAIII. Sorted cells were lysed and 128 
the RNA extractions, cDNA synthesis and PCR performed as per the manufacturer’s 129 
instructions. PCR products were run on a 4% agarose gel and visualized on a GelDoc system 130 
(BioRad, Hertfordshire, UK). 131 
 132 
Statistics 133 
Data is shown as mean ± SD. Groups were compared using one-way ANOVA or unpaired 134 
Student’s t test. Specific tests and significance levels are stated in the appropriate figure legends. 135 
Using data from previous studies 12 17 we estimated that a minimum of three animals per time 136 
point/group would provide 80% power to detect significant differences (p<0.05) in numbers of T 137 
cells induced following antigen challenge versus carrier alone. Statistical analysis of results was 138 
performed using Prism version 6 (GraphPad, Inc, CA, USA).  139 
 140 
  141 
Results  142 
Characterising T cell recruitment to the joint 143 
Employing a previously described model of articular inflammation displaying histological 144 
evidence of bone and cartilage remodeling and autoreactive T and B cell responses 9 15-19, we 145 
determined appropriate timings to visualize articular T cell and DC behaviour by detailing the 146 
kinetics of cellular recruitment ex vivo (Supplementary figure 1A). Induction of arthritis using 147 
heat aggregated ovalbumin (HAO) resulted in an influx of neutrophils, dendritic cells, and CD4+ 148 
T cells to the joint (Supplementary figure 1B-F). Maximal accumulation of DCs and CD4+ T 149 
cells occurred at day 4, with distinguishable populations observed for donor transferred OT-II 150 
cells and endogenous CD45.1-CD4+ T cells (Supplementary figure 1E-F). OT-II T cells were the 151 
minor T cell population relative to endogenous CD4+ T cells (Figure 1A, B). Both transferred 152 
OT-II cells and endogenous CD4+ T cells infiltrating the joint displayed an activated 153 
proinflammatory phenotype, being CD44hiCD62Llo/neg and produced TNFα and IFNγ following 154 
ex vivo stimulation with PMA/ionomycin (Figure 1C, D). Notably, endogenous CD4+ T cells 155 
from popliteal lymph nodes (pLN) only produced TNFα upon restimulation, suggesting that 156 
subsequent reactivation in the target tissue contributed to further differentiation allowing 157 
production of IFNγ (Figure 1E). We tested the possibility that a proportion of these endogenous 158 
T cells may be specific for OVA, having been primed in response to immunization with 159 
OVA/CFA used to maintain the transferred OT-II cells. T cells were FACS sorted from inflamed 160 
joints and popliteal LNs for co-culture with OVA-pulsed bone-marrow derived DCs. The very 161 
low numbers of T cells recovered from the inflamed joint proved prohibitive to performing a 162 
robust analysis. However, T cells sorted from the popliteal LN showed endogenous T cells did 163 
not respond to OVA-pulsed bone-marrow derived DCs whereas OT-II T cells significantly 164 
increased expression of ICOS and CD44 (Supplementary Figure 2A). In addition, ex vivo 165 
stimulation of unfractioned cells with OVA323-339 revealed that OT-II T cells from inflamed 166 
joints and pLNs were able to respond, whereas the endogenous T cells were not (Supplementary 167 
Figure S2B-E). Thus, while the specificity of these cells remains unknown, the majority are 168 
unlikely to be specific for the immunodominant epitope of the inciting antigen. 169 
 170 
T cells and DC undergo long-lived interactions in the joint  171 
Having established the recruitment kinetics of CD4+ T cells into the joint, we next visualized 172 
their behaviour using intravital multiphoton laser scanning microscopy (MPLSM) and lineage 173 
specific fluorescent reporter mice (Supplementary Figure S3, Supplementary Movie S1). 174 
Following periarticular injection of HAO, a rare population of slow moving and stationary OT-II 175 
DsRed articular T cells were consistently observed (Figure 2A, Movie 1). Their typical 176 
behavioural parameters namely low speed, displacement rate and meandering index (Figure 2C-177 
E) were consistent with recognition of cognate antigen and consequent local activation 21-23. This 178 
was reflected in the proportion of OT-II cells interacting with fluorescent DCs for longer than 10 179 
minutes (Figure 2F). Clustering of CD11c-YFP cells was also observed around tendons and the 180 
joint capsule.  181 
 182 
To investigate the behaviour of infiltrating endogenous T cells, we crossed CD11c-YFP mice to 183 
intact hCD2-DsRed mice (CD11c-YFPxDsRed), allowing analysis of endogenous T cell 184 
interactions.  Induction of articular inflammation resulted in recruitment of endogenous T cells to 185 
the joint (Figure 2B, Movie 2) – these T cells exhibited a broader range of speeds, displacement 186 
rate and meandering index than the monoclonal antigen-specific OT-II population (Figure 2C-E). 187 
Notably, some endogenous T cells displayed behaviour consistent with recognition of antigen 188 
and activation, moving slowly and remaining in contact with CD11c+ cells for longer than 10 189 
minutes (Figure 2F). In parallel, many cells exhibited scanning behaviour, moving quickly from 190 
DC to DC, only contacting for short periods of less than 5 minutes (Figure 2F).   Thus, OT-II and 191 
a sub-population of endogenous T cells interact with CD11c+ cells within the inflamed articular 192 
environment in a manner consistent with antigen recognition and activation.  193 
 194 
Heterogeneity in motility of endogenous CD4+ T cells likely arises from diversity of antigen 195 
specificity. Given the evidence of broader autoreactive responses in this model 9 15-17 19, and in 196 
RA patients 1, it seemed unlikely that a monoclonal T cell clone would dominate the 197 
inflammatory infiltrate. Therefore, in the absence of information regarding the target antigens of 198 
the endogenous T cells, we probed T cell receptor (TCR) use as in indicator of diversity among 199 
articular endogenous CD4+ T cells. By performing Vβ complementarity determining region 3 200 
(CDR3) clonality analyses we were able to assess whether there was selective accumulation of 201 
few or multiple T cell clones.  CD4+ T cells from naive LN displayed diverse Vβ usage 202 
consistent with multiple (poly)clonality (Supplementary Figure 4A). Diversity was also broad in 203 
LNs draining the inflamed site - all Vβ were expressed with the exception of Vβ13 204 
(Supplementary Figure 4B). By contrast, when articular T cells were examined, although the 205 
majority of Vβ chains were represented, only one or two CDR3 clones were identified per Vβ 206 
used (Supplementary Figure 4C). While the reduced clonality of Vβ use by the joint infiltrating 207 
CD4+ T cell population implies a role for antigen, the number of Vβ chains present may also 208 
explain the heterogeneity in behaviour seen in our imaging studies. 209 
 210 
CD4+ T cells of irrelevant specificity can be recruited to the inflamed joint.  211 
To assess recruitment of effector/memory CD4+ T cells of unrelated/irrelevant antigen 212 
specificity, we adoptively transferred Th1 polarised TEa TCR transgenic CD4+ T cells (specific 213 
for Eα52-68 I-Ab) into congenic recipients and induced arthritis in the absence or presence of their 214 
cognate antigen (HAO or HAO + Eα respectively). Induction of arthritis recruited Th1 OT-II into 215 
the joint as expected, however a significant population of TEa Th1 cells were also detected 216 
(Figure 3A, B). Induction of arthritis with HAO and Eα52-68 (HAO + Eα) did not significantly 217 
increase numbers of TEa in the inflamed tissue (Figure 3A, B) but was required for their up-218 
regulation of inducible costimulatory (ICOS) molecule expression (Figure 3C, D) and expansion 219 
of TEa in the pLN (Figure 3E, F). Thus, the presence of a diverse TCR repertoire and the 220 
observation that a proportion of T cells continually exhibit scanning behaviour at the inflamed 221 
site could therefore be explained by recruitment of antigen experienced cells of an irrelevant 222 
antigen specificity.  223 
 224 
Abatacept has no immediate impact on T cell/DC interactions in the inflamed joint. 225 
As well as its clinical success 24, abatacept is also effective in murine models of disease 25-27. 226 
Abatacept, a CTLA4-Ig fusion protein, targets one of the most important co-stimulators of T cell 227 
activation, blocking binding of T cell CD28 to CD80/CD86 on antigen presenting cells (APCs) 228 
28-30. Previously we reported abatacept inhibition of pathology in our arthritis model 18 and the 229 
priming of LN T cells 31. We extended these studies to determine the effect of abatacept upon the 230 
intra-articular T cell response. Mice were treated with abatacept one day prior to HAO challenge 231 
and then on day 1 and day 3 post-challenge. To assess whether abatacept could have a more 232 
immediate impact on T cell/DC communication, a single administration of drug was given 6 233 
hours prior to tissue harvesting. Abatacept treatment, either throughout or 6 hours prior to 234 
harvest, resulted in reduced accumulation of endogenous T cells in the joint (Figure 4A, B), but 235 
did not impact on OT-II articular accumulation (Figure 4A, C). A failure to prime endogenous T 236 
cells in the pLN was found to underpin their failed accumulation in the joint (Supplementary 237 
Figure S5). Although abatacept treatment did not significantly alter OT-II proportions in the joint 238 
draining LNs, it did prevent the upregulation of ICOS (Supplementary Figure S6). Abatacept 239 
treatment also impacted upon reactivation of endogenous and donor T cells in the joint evidenced 240 
as lower ICOS expression, even when given 6 hours prior to harvesting of cells (Figure 4D, E 241 
respectively).  242 
 243 
Consistent with the flow cytometry data, MPLSM of PBS challenged joints revealed few T cells 244 
or DCs, whereas a large population of endogenous T cells was observed after HAO challenge 245 
(Figure 5A, Movie 3). Abatacept treatment throughout reduced endogenous T cell infiltration of 246 
inflamed joints (Figure 5A, Movie 3), consistent with our flow data. T cells that were observed 247 
exhibited reduced speed (Figure 5B). The displacement rate (Figure 5C), directionality of their 248 
movement (meandering index, Figure 5D) and interaction time with DCs (Figure 5E) appeared to 249 
be unaffected. Previous studies show that motility is influenced by numerous extrinsic factors 250 
(reviewed in 32). Published data suggests that the availability of such factors is altered/limited in 251 
the reduced inflammatory environment post abatacept treatment 18. Abatacept treatment 6 hours 252 
prior to imaging did not impact on T cell speed, displacement rate, meandering index or 253 
interaction times with articular DCs (Figure 5A-E, Movie 3). Anti-TNF (etanercept), given as an 254 
additional control 6 hours prior to imaging, similarly had no impact on the behaviour of T cells 255 
in the joint (Figure 5A-E, Movie 3). Although abatacept did not alter endogenous T cell/DC 256 
articular interactions, even 6 hours of localized exposure was sufficient to reduce expression of 257 
ICOS, indicative of continued dialogue between APC and T cell in the inflamed joint. Abatacept 258 
is therefore able to affect the re-activation of T cells within the inflamed joint itself.  259 
 260 
Discussion  261 
We present the first examination of the dynamics of T cell recruitment and interactions in the 262 
articular environment. Using a model of early articular inflammation, we find that recruitment of 263 
a small population of antigen-specific CD4+ T cells is paralleled by influx of a larger oligoclonal 264 
CD4+ T cell population, a significant proportion of which engages with DCs in a manner 265 
consistent with recognition of cognate antigen. Signaling through CD28 was not required for 266 
ongoing articular interactions, but was critical for full activation of CD4+ T cells in the joint. 267 
These findings not only enhance our fundamental understanding of the location and dynamics of 268 
the cellular interactions that control the development of articular inflammation, but will also be 269 
informative for future studies in clinical RA examining the evolution of articular T cell 270 
responses.  271 
  272 
Genetic studies have implicated CD4+ T cells in the pathogenesis of RA 2-6. Consistent with this, 273 
our model displayed recruitment of immune system cells, including neutrophils, macrophages, B 274 
cells, DCs, and crucially, CD4+ T cells.  These T cells displayed an antigen-experienced 275 
phenotype with the potential to produce pro-inflammatory TNFα and IFNγ. As expected, an 276 
increased proportion of CD4+ T cells capable of producing TNFα were found in the LN draining 277 
the inflamed joint. It has long been known that T cells in somatic tissues have a memory 278 
phenotype and T cells in the inflamed joint also have an antigen experienced phenotype.   279 
However, the role of antigen in the recruitment, retention or activation of memory T cells 280 
remains unclear. To address this, we imaged T-DC interactions in the joint. 281 
 282 
The dynamics of T cell interactions with DC have been characterised using in vivo imaging and 283 
revealed particular behaviours indicative of certain outcomes. For example, activation of T cells 284 
in LN occurs with three phases: the first (typically the initial 8 hours of antigen exposure) is 285 
characterised by transient interactions (<5 minutes); the second, 8–20 hours after exposure to 286 
antigen, is characterized by long lived T cell/DC interactions (>10 minutes) reflecting 287 
recognition of cognate antigen and costimulation, underpinning priming of the T cell 21 22 33; after 288 
~48 hours, T cells recover motility and subsequent interactions with DCs are short. Equally, 289 
these interactions can also impact on T cell differentiation 12 and even tolerance 23 34. Our studies 290 
directly demonstrate stable interactions between endogenous CD4+ T cells and DCs in the 291 
inflamed joint consistent with recognition of specific antigen. These interactions likely underpin 292 
our observation that TNFα producing T cells in the joint co-expressed IFNγ unlike their 293 
counterparts in the joint draining lymph node. A similar “two hit” theory has already been 294 
proposed for IL-4 production 35 36.  295 
 296 
Although the specificity of T cells in RA joints remains unclear, diversity in TCR expression by 297 
synovial T cells is reduced, indicating their selective accumulation 37-40. Notably, comparable 298 
clonal responses are detected in healthy siblings of RA sufferers 41. Thus, changes in clonality of 299 
the response are likely to occur early in disease and reflect disease status. Indeed, selected Vβ 300 
clonal expansion seen in peripheral blood of RA patients 42 is reduced in the face of successful 301 
anti-TNFα therapy 43, indicating alterations in repertoire can inform as to responsiveness to 302 
therapeutic intervention.  Endogenous T cells infiltrating joints in our model exhibited reduced 303 
Vβ CDR3 repertoire diversity, consistent with the oligoclonal nature of human RA synovial T 304 
cells 39 44-46. The similarity in clonal responses in the joint and draining LN also supports the 305 
hypothesis that T cell activation and clonal expansion occurs in secondary lymphoid organs prior 306 
to migration and accumulation in the joint. Given the propensity for autoreactivity arising in the 307 
endogenous CD4+ T cell compartment in our model 9 and the observation of sustained 308 
interactions with DCs in the inflamed joint, our data supports a model where autoreactive T cells 309 
may constitute a small but significant population of articular infiltrating T cells and that cognate 310 
interactions with DCs would support their activation/proliferation in response to local antigen 47 311 
48. 312 
 313 
As some endogenous T cells did not undergo interactions with DC in the inflamed joint and the 314 
TCR usage analysis demonstrated an oligoclonal response we tested whether activated/memory 315 
T cells of irrelevant antigen-specificity could be recruited to the inflamed joint. Indeed, a range 316 
of viral and bacterial T cell specificities have been identified in RA synovial tissue 49, and 317 
consistent with this, we directly demonstrated that irrelevant-specificity CD4+ T cells can be 318 
recruited to the inflamed joint independently of cognate antigen. Such memory T cells may be 319 
activated by the inflammatory environment as reported by Brennan 50 51 and others 52-54 in the 320 
instance of cytokine-activated T cells (Tck). While recruitment of irrelevant specificity T cells 321 
was not dependent upon cognate antigen, the latter was required for up-regulation of ICOS, 322 
stressing the importance of cognate T/DC interaction in the inflamed joint for full T cell 323 
activation.  324 
 325 
As we found antigen-specific, oligoclonal and unrelated T cells in the joint we examined whether 326 
a current therapeutic targeting T-DC interactions affected these cells in the joint or draining LN.  327 
While abatacept did not directly inhibit the ability of T cells and DCs to interact in the inflamed 328 
joint, the diminished ability of these T cells to up-regulate ICOS suggested a failure in their 329 
activation. Thus, in addition to inhibiting priming of potentially autoreactive T cells in the joint 330 
draining LN, abatacept influences the quality of DC-T cell interactions directly in the inflamed 331 
joint.  332 
 333 
In conclusion, our findings demonstrate that T cells make cognate interactions with DCs 334 
in the inflamed joint. Recruitment of a small number of inciting-antigen-specific T cells into the 335 
joint environment is paralleled by a larger oligoclonal population of pro-inflammatory CD4+ T 336 
cells, a proportion of which interact with DCs in a manner consistent with recognition of cognate 337 
antigen. We also demonstrate that T cells of irrelevant specificity can enter the joint. However, 338 
recognition of cognate antigen with costimulation is necessary for full activation in the articular 339 
environment.  340 
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Figure 1: CD4+ T cells recruited to the joint have an activated, proinflammatory 520 
phenotype. (A) Representative flow cytometry plots, gated on viable CD45+ cells isolated from 521 
the joints on day 4 post PBS or HAO periarticular challenge, showing the expression of CD4 and 522 
CD45.1 representing the endogenous T cells (CD4+CD45.1-) and donor OT-II T cells 523 
(CD4+CD45.1+). (B) Absolute number of OT-II donor T cells and endogenous T cells isolated 524 
from the joints after PBS or HAO periarticular challenge. (C) Representative flow cytometry 525 
plots of CD44 and CD62L expression by OT-II donor T cells and endogenous CD4+ T cells from 526 
inflamed joints.  (D) IFNγ and TNFα production by cells was assessed following 527 
PMA/Ionomycin ex vivo re-stimulation. Representative flow cytometry plots showing IFNγ and 528 
TNFα responses of OT-II donor and endogenous CD4+ T cells isolated from joints. (E) 529 
Percentage of TNFα expressing endogenous and OT-II donor that co-express IFNγ at both 530 
draining popliteal LN and joint in HAO challenged mice. Data shows the mean with points 531 
representing individual experimental animals. Data is representative of three individual 532 
experiments, * represents p<0.05; ** represents p<0.01; *** represents p<0.001. 533 
 534 
Figure 2. Imaging T cell interactions with DCs within the joint. Adoptive transfer of DsRed 535 
OT-II Th1 cells into CD11cYFP recipients allowed visualization of antigen specific T cell/DC 536 
interactions in the inflamed articular microenvironment (A), while crossing CD11cYFP animals 537 
with CD2DsRed transgenic mice allowed imaging of endogenous T cell interactions with DCs 538 
(B) in our T cell dependent model of arthritis. Arthritis was induced by periarticular injection of 539 
heat aggregated ovalbumin (HAO) as before and MPLSM of inciting-antigen specific OT-II T 540 
cells or endogenous T cells interacting with DCs in the inflamed articular environment 541 
performed four days later. T cells are seen in red, DCs in green and SHG from collagen structure 542 
in blue.  T cell speed (C), displacement rate (D), meandering index (E) and duration of 543 
interaction with DCs (F) were determined using Volocity image analysis software for three fields 544 
of view and three animals. Data shows the mean with points representing individual cells. Data is 545 
representative of two independent experiments. Scale bars represent 50 µm.  546 
 547 
Figure 3: Antigen experienced Th1 cells of irrelevant specificity can be recruited to the 548 
inflamed joint. OT-II Th1 cells (DSRed) and TEa Th1 cells (CD45.2+) were transferred into 549 
CD45.1 B6 hosts and mice subsequently challenged in the footpad with PBS, HAO or HAO + 550 
Eα52-68. (A) Each transferred T cell population could be tracked in the CD45.1 B6 hosts based on 551 
their expression of either DSRed (OT-II T cells) or CD45.2 (TEa T cells). Representative flow 552 
cytometry plots, previously gated on the CD45+ CD4+ T cells in the joint showing expression of 553 
CD45.2 and DSRed. (B) Absolute number of CD45.2+ TEa T cells in the joint after PBS, HAO 554 
only or HAO + Eα challenge. (C) Representative flow cytometry plots showing CD44 and ICOS 555 
expression on CD45.2+ TEa T cells in the joint after PBS, HAO only or HAO + Eα challenge. 556 
(D) Absolute number of ICOS+ CD45.2+ TEa T cells in the joint after PBS, HAO only or HAO + 557 
Eα challenge. (E) Percentage of CD45.2+ TEa T cells in the draining lymph node (popliteal LN) 558 
as a percentage of total CD4+ T cells and (F) absolute number of CD45.2+ TEa T cells in the 559 
draining lymph node after PBS, HAO only or HAO + Eα challenge. Data representative of two 560 
independent experiments; n=5 mice per group. ** represents p<0.01; *** represents p<0.001. 561 
 562 
Figure 4. The therapeutic impact of abatacept on CD4+ T cell accumulation in inflamed 563 
joints. C57BL/6J recipient mice were adoptively transferred with OT-II Th1 cells, boosted with 564 
OVA/CFA and periarticularly challenged with PBS or HAO (as in Figure S1A). In addition, 565 
mice were either treated throughout with abatacept (Aba) (given 24 hours prior to footpad 566 
challenge and every 2 days thereafter) or 6 hours prior to harvest of the tissues. Mice were taken 567 
4 days after footpad challenge. Single cell suspension of inflamed joints were analysed by flow 568 
cytometry to determine the proportions of endogenous and inciting-antigen-specific Th1 OT-II 569 
cells accumulating after challenge. (A) Representative flow cytometry plots showing both 570 
endogenous (CD4+CD45.1-) and OT-II (CD4+CD45.1+) T cells on day 4 post-challenge with 571 
PBS or HAO. Proportions of viable leukocytes isolated from joints found to be (B) endogenous 572 
CD4+CD45.1- T cells and (C) CD4+CD45.1+ OT-II cells. Proportion of ICOS expressing (D) 573 
endogenous CD4+ T cells and (E) OT-II donor T cells isolated from PBS, HAO with IgG isotype 574 
control, HAO with abatacept throughout or HAO with abatacept 6 hours prior to harvest. Data is 575 
representative of 3 experiments; n=5 mice. * represents p<0.05; ** represents p<0.01; *** 576 
represents p<0.001; **** represents p<0.0001.  577 
 578 
Figure 5. Imaging T cell/DC interactions in response to abatacept. CD11cYFPxDsRed 579 
recipient mice were adoptively transferred with non-fluorescent OT-II Th1 cells, boosted with 580 
OVA/CFA and periarticularly challenged with PBS or HAO (as in Figure S1A). In addition, 581 
mice were either treated throughout with Abatacept (Aba) (given 24 hours prior to challenge and 582 
every 2 days thereafter) or 6 hours prior to imaging. MPLSM of ankle joints was performed on 583 
day 4 following challenge. In addition, one group received Etanercept (Etan) given 6 hours prior 584 
to imaging. (A) Representative MPLSM images showing CD11c+ cells (yellow), endogenous T 585 
cells (red) and SHG from joint capsule and tendon (blue). Cell tracking was performed to 586 
determine T cell (B) speed, (C) displacement rate, (D) meandering index and (E) duration of 587 
contact with CD11c+ cells using Volocity image analysis software for three fields of view and 588 
three animals. Data shows the mean with points representing individual cells. Data is 589 
representative of two independent experiments. Scale bars represent 50 µm. 590 
  591 
Supplementary Figure S1. CD4+ T cell recruitment to inflamed joints. Flow cytometry was 592 
used to establish the kinetics of cellular infiltrate of joints. (A) A CD4+ T cell dependent model 593 
of articular inflammation using trackable antigen specific T cells was used to allow tracking of 594 
inciting CD4+ T cell responses. Infiltration of CD11b+Ly6G+ neutrophils (B), CD11b+CD11c+ 595 
dendritic cells (C), CD19+ B cells (D), endogenous CD4+CD45.1- T cells (E) and CD4+CD45.1+ 596 
donor OT-II T cells (F) to inflamed joints was determined by flow cytometry on days 1, 4, 7 and 597 
21 post PBS or HAO challenge. Data shows percentage (%) of total cells recovered from the 598 
joint. Data representative of two independent experiments; n=3-4 mice per group. * represents 599 
p<0.05.  600 
 601 
Supplementary Figure S2.  Endogenous T cells isolated from joints and draining LN do not 602 
make significant responses to OVA. CD4+ T cells were FACsorted from pooled pLNs on day 4 603 
post-HAO challenge and co-cultured with OVA-pulsed BMDC. (A) Percentage of OT-II donor T 604 
cells and endogenous T cells from pLN expressing CD44 and ICOS after co-culture with 605 
medium or OVA-pulsed BMDC. T cells were FACsorted from a pool of 20 mice; data shows 4 606 
technical replicates. IFNγ and TNFα production by cells was assessed following medium or 607 
OVA323-339 (OVAp) ex vivo re-stimulation. (B) Representative flow cytometry plots showing 608 
IFNγ and TNFα responses of OT-II donor (CD4+CD45.1+) and endogenous CD4+ T cells 609 
(CD4+CD45.1-) isolated from joints. (C) Percentage of OT-II donor T cells and endogenous T 610 
cells from joints that produced cytokine (either IFNγ or TNFα or both) in response to 611 
stimulation. (D) Representative flow cytometry plots showing IFNγ and TNFα responses of OT-612 
II donor (CD4+CD45.1+) and endogenous CD4+ T cells (CD4+CD45.1-) from joint draining 613 
pLNs. (E) Percentage of OT-II donor T cells and endogenous T cells from joint draining pLNs 614 
that produced cytokine in response to stimulation (either IFNγ or TNFα or both). Data shows 615 
five individual mice, *** represents p<0.0001; *** represents p<0.001. 616 
 617 
Supplementary Figure S3.  MPLSM was used to image the ankle in real time from a medial 618 
aspect (A), with anaesthetized mice being transferred to a warmed saline bath prior to imaging 619 
(B). Second harmonic generation (SHG) localized tendons to allow anatomical localization and 620 
orientation (C). The validity of our methodology was confirmed by imaging responses in LysM-621 
GFP reporter mice during collagen-antibody-induced-arthritis (CAIA). Neutrophils were not 622 
observed in the control joint (D) however they were abundant in the inflamed joint (E), 623 
consistent with ex vivo confirmatory flow cytometry analysis (F). Neutrophils were highly 624 
motile, consistent with other studies of neutrophil behaviour in inflamed joints. Mean cell 625 
proportions of 5 mice per group are shown. MPLSM images are representative of 7 mice. 626 
 627 
Supplementary Figure S4: TCR diversity in endogenous CD4+ T cells recruited to the 628 
inflamed joint. To determine TCR diversity of endogenous CD4+ T cells infiltrating the draining 629 
lymph nodes and the joints, endogenous CD4+CD44hi T cells were sorted by FACS from naïve 630 
C57BL/6J popliteal lymph nodes (A), joint-draining lymph nodes (popliteal) (B) and inflamed 631 
joints (C) 4 days post HAO challenge. PCR was performed to determine the clonality of these 632 
cells for each Vβ using the SuperTCRExpress kit (BioMed Immunotech). Endogenous T cells 633 
were sorted from pooled samples (naïve n=3; HAO popliteal LN n=20; HAO joint n=20 mice). 634 
pLN denotes popliteal lymph node. Numbers above represent each Vβ; ‘L’ denotes DNA ladder; 635 
‘-‘ denotes negative control; ‘+’ denotes positive control.  Data is representative of three 636 
independent experiments. 637 
 638 
Supplementary Figure S5. Abatacept treatment inhibits CD4+ T cell activation in the joint 639 
draining lymph node. C57BL/6J recipient mice were adoptively transferred with OT-II Th1 640 
cells, boosted with OVA/CFA and periarticularly challenged with PBS or HAO (as in Figure 641 
S1A). In addition, mice were either treated throughout with IgG isotype control or abatacept 642 
(given 24 hours prior to footpad challenge and every 2 days thereafter). Mice were taken 4 days 643 
after footpad challenge. Single cell suspension of draining lymph nodes (popliteal LNs) were 644 
analysed by flow cytometry. Absolute number of (A) total cells and (B) endogenous CD4 T cells 645 
in the popliteal LNs after PBS or HAO challenge and treatment with IgG or abatacept. (C) 646 
Representative flow plots showing expression of CD44 and CD62L on endogenous CD4+ T 647 
cells. (D) Percentage of endogenous CD4+ T cells that are CD44hiCD62Llo in the popliteal LN 648 
after PBS or HAO challenge. (E) Representative flow plots of ICOS expression on endogenous 649 
CD4+ T cells. (F) Percentage of endogenous CD4+ T cells that are ICOS+ in the popliteal LN 650 
after PBS or HAO challenge and treatment with IgG or abatacept. Data is representative of 3 651 
experiments; n=5 mice per group. **** represents p<0.0001. 652 
 653 
Supplementary Figure S6. Abatacept inhibits ICOS expression by antigen experienced 654 
CD4+ T cell donor cells in the joint draining lymph node. C57BL/6J recipient mice were 655 
adoptively transferred with OT-II Th1 cells, boosted with OVA/CFA and periarticularly 656 
challenged with PBS or HAO (as in Figure S1A). In addition, mice were either treated 657 
throughout with IgG isotype control or abatacept (given 24 hours prior to footpad challenge and 658 
every 2 days thereafter). Mice were taken 4 days after footpad challenge. Single cell suspension 659 
of draining lymph nodes (popliteal LNs) were analysed by flow cytometry. Proportion (A) and 660 
absolute number (B) of donor OT-II cells in the popliteal LNs after PBS or HAO challenge and 661 
treatment with IgG or abatacept are shown. (C) Representative flow plots showing expression of 662 
CD44 and CD62L on donor OT-II CD4+ T cells. (D) Percentage of donor OT-II CD4+ T cells 663 
that are CD44hiCD62Llo in the popliteal LN after PBS or HAO challenge with isotype control or 664 
abatacept. (E) Representative flow plots of ICOS expression by OT-II CD4+ T cells. (F) 665 
Percentage of endogenous CD4+ T cells that are ICOS+ in the popliteal LN after PBS or HAO 666 
challenge and treatment with IgG or abatacept. Data is representative of 3 experiments; n=5 mice 667 
per group. **** represents p<0.0001. 668 
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Movies 670 
 671 
1. Movie 1: Dynamics of OT-II T cell interactions with DCs in the inflamed joint. 672 
 673 
2. Movie 2: Dynamics of endogenous T cell interactions with DCs in the inflamed joint. 674 
 675 
3. Movie 3: Endogenous T cell/DC interactions in PBS, HAO challenged joints, with abatacept 676 
throughout, abatacept 6hrs or etanercept 6hrs prior to imaging. 677 
 678 
Supplementary Movies 679 
1. Supplementary movie S1: Intravital MPLSM imaging of non-arthritic joints and CAIA 680 
arthritic joints in LysMGFP mice. 681 
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